Ginkgo Biloba — Research Profile

The evidence is nuanced. For healthy young adults, ginkgo shows minimal cognitive benefit. For older adults with existing mild cognitive impairment or early dementia, standardized EGb 761 at 240mg/day consistently shows modest improvements in memory, attention, and daily functioning across European trials ^[1][4]. A 2020 meta-analysis of seven Alzheimer's trials (n=939) confirmed significant cognitive and global clinical improvements ^[12]. It is not a memory miracle pill, but it has real, clinically validated effects in the right population.

Ginkgo should be used with caution alongside blood thinners. Its ginkgolides inhibit platelet-activating factor (PAF), which can theoretically increase bleeding risk. While clinical trials have not consistently shown dangerous interactions, most guidelines recommend avoiding the combination or using only under medical supervision. Stop ginkgo at least 2 weeks before surgery.

Most clinical trials measure outcomes at 8-12 weeks, with some showing initial improvements by 4-6 weeks. Ginkgo works through gradual improvements in cerebral blood flow and antioxidant protection rather than acute stimulation. Consistent daily use for at least 8 weeks is recommended before evaluating effectiveness.

The best-studied form is the standardized leaf extract EGb 761, given as an oral tablet or capsule at 120 to 240 mg/day; this is the preparation behind essentially all of the trial data. There is no evidence that whole-leaf teas, tinctures, or seed preparations perform as well, and seeds are actually toxic. If you use ginkgo at all, use a standardized leaf extract.

Honestly, there is no conclusively proven benefit for any health condition. Two large prevention trials found ginkgo did not lower dementia or Alzheimer's risk: the GEM trial (3,069 adults 75+, median 6.1 years) showed a hazard ratio of 1.16 for Alzheimer's, and GuidAge (2,854 adults 70+, 5 years) found no significant reduction. The one signal is modest: in people who already have cognitive impairment or dementia, EGb 761 240 mg/day produced small improvements in cognition and daily function over 22 to 26 weeks.

Ginkgo is not a nutrient, so there is no RDA; trials have used 120 to 240 mg/day of standardized extract, with 240 mg/day being the dose associated with the modest cognitive effects in dementia research. Prevention trials used 120 mg twice daily (240 mg total). No dosing has been established for healthy people because a benefit in that group has not been demonstrated.

No study has directly compared morning versus evening dosing, so an optimal time of day is not established. Trials simply gave it either once daily or split as 120 mg twice a day, and both schedules were used in the dementia research. Pick a schedule you can keep consistently rather than a specific clock time.

The most commonly reported side effects are dizziness, gastrointestinal symptoms, and headache. Ginkgo also has antiplatelet activity, and human studies and case reports link it to prolonged bleeding time and spontaneous bleeding, so bleeding is a real concern rather than a purely theoretical one. Fresh or roasted seeds, unlike the standardized leaf extract, can cause serious toxicity.

The best-established caution is with anticoagulant and antiplatelet drugs such as warfarin, where ginkgo may increase bleeding risk and the combination is generally avoided. Its antiplatelet activity can prolong bleeding time, and laboratory studies and case reports suggest it may also inhibit or induce CYP450 enzymes (1A2, 2D6, 3A4), though those metabolic data are conflicting. Anyone on blood thinners or facing surgery should not combine it without medical clearance, and it should be avoided near delivery because of bleeding risk.

Given that large trials found no benefit for preventing dementia in older adults and no proven benefit in healthy people, there is no group for whom the evidence strongly supports ginkgo. The only setting with even a modest signal is existing mild cognitive impairment or dementia, where standardized extract produced small effects. It should be avoided by people on anticoagulants, those scheduled for surgery, and during pregnancy, where it may trigger early labor or bleeding.

There is no rapid, reliably measurable effect; in the trials where standardized extract (EGb 761) showed any benefit for cognitive impairment and dementia, cognition and daily-function outcomes were assessed after 22 to 26 weeks of 240 mg/day dosing. In healthy adults without cognitive impairment, ginkgo has not been shown to improve memory or mental performance at any timeframe. Expect to judge it over months rather than days, and understand the evidence for benefit is weak even then.

Ginkgo leaf extract has been used in research for as long as 6 years without important safety concerns emerging. The GEM trial gave 3,069 adults aged 75 or older 120 mg twice daily for a median of 6.1 years and found no excess safety signal, though it also found no reduction in dementia. So long-term use appears tolerable, but that tolerability is not paired with a clear proven benefit to justify it.

No formal tolerable upper limit is established for the standardized leaf extract; clinical trials have gone up to about 240 mg/day without dose-related toxicity. The real toxicity concern is the seed, not the leaf extract: fresh ginkgo seeds are toxic when eaten, and serious reactions have occurred even with roasted seeds. Stay with a standardized leaf-extract product and avoid raw or roasted seeds entirely.

The main caution is stacking ginkgo with other supplements that can affect bleeding, such as fish oil, vitamin E, or high-dose garlic. Ginkgo has antiplatelet activity, and human studies and case reports indicate it may prolong bleeding time, so additive effects with other bleeding-risk products are plausible rather than merely theoretical. There is no evidence that combining it with typical vitamins or minerals is harmful, so the specific watch-point is other supplements that thin the blood.

Choose a standardized leaf extract matching the material used in clinical trials: EGb 761 (sold as Tebonin), standardized to roughly 24% flavone glycosides and 6% terpene lactones (ginkgolides and bilobalide). Products that list only 'ginkgo leaf powder' without those standardization percentages have not been characterized the way the studied extract was. Avoid anything containing seeds, which are toxic.